FDA approves J&J’s Icotyde for plaque psoriasis

Johnson & Johnson said the US Food and Drug Administration approved Icotyde (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and in pediatric patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The drug is a once-daily oral peptide that targets the IL-23 receptor, and J&J is positioning it as the first approved therapy in that class. The approval follows the company’s Phase 3 ICONIC program, including ICONIC-LEAD and ICONIC-ADVANCE 1 and 2, which showed strong skin-clearance results and favorable safety findings versus placebo, with head-to-head superiority over deucravacitinib reported in the ADVANCE trials. (investor.jnj.com)

Why it matters: This is a human dermatology approval, not a veterinary one, but it matters for veterinary professionals as a signal of where immune-mediated inflammatory drug development is heading: more oral, targeted cytokine-pathway therapies, and more pressure to deliver biologic-like efficacy without injections. For clinicians and industry teams watching translational immunology, icotrokinra adds momentum to IL-23 pathway targeting and may shape expectations among pet parents who increasingly follow human advances in chronic inflammatory disease care. It also reinforces how competitive the oral immunology market has become, with Takeda advancing zasocitinib in late-stage plaque psoriasis studies presented at AAD 2026. (investor.jnj.com)

What to watch: Watch for payer coverage, real-world uptake, and whether IL-23-directed oral approaches begin influencing companion-animal immunodermatology research or pet parent expectations around chronic skin disease treatment. (investor.jnj.com)